Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will
release its 2010 fourth quarter and year-end financial results on
Thursday March 10, 2011 at approximately 8:30 am ET / 5:30 am PT . The
company is not hosting a conference call with regards to this
announcement.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing
and commercializing novel small-molecule therapeutics derived from its
boron chemistry platform. Anacor has discovered five clinical compounds
which are currently in development, including its three lead programs:
AN2690, a topical antifungal for the treatment of onychomycosis; AN2728,
a topical anti-inflammatory PDE-4 inhibitor for the treatment of
psoriasis; and GSK 2251052, or GSK ‘052 (formerly referred to as
AN3365), a systemic antibiotic for the treatment of infections caused by
Gram-negative bacteria, which has been licensed to GlaxoSmithKline under
the companies' research and development agreement. In addition, Anacor
is developing AN2718 as a topical antifungal product candidate for the
treatment of onychomycosis and skin fungal infections, and AN2898 as a
topical anti-inflammatory product candidate for the treatment of
psoriasis and atopic dermatitis. For more information visit http://www.anacor.com.
